19,000 results on '"Leukemia, Myelogenous, Chronic, BCR-ABL Positive"'
Search Results
252. Bone Marrow and Kidney Transplant for Patients With Chronic Kidney Disease and Blood Disorders (BMT)
253. Thymoglobuline Versus Alemtuzumab in Patients Undergoing Allogeneic Transplant (GLOBAL)
254. The Life After Stopping Tyrosine Kinase Inhibitors Study (The LAST Study)
255. A Study to Evaluate Available Treatment Information of Ponatinib, Bosutinib, Imatinib, Dasatinib and Nilotinib in Adults With Chronic Myeloid Leukemia
256. MargheRITA (Remote Intelligence for Therapeutic Adherence) (MargheRITA)
257. UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep
258. Phase I Trial of Universal Donor NK Cell Therapy in Combination With ALT803
259. Engineered Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies
260. A Phase I, Dose-finding Study of BEZ235 in Adult Patients With Relapsed or Refractory Acute Leukemia
261. A Distress Reduction Intervention for Patients With BCR-ABL-Negative MPNs or CML on Tyrosine Kinase Inhibitors
262. Expanded/Activated Gamma Delta T-cell Infusion Following Hematopoietic Stem Cell Transplantation and Post-transplant Cyclophosphamide
263. DC Vaccination in CML
264. Natural History and Biology of Long-Term Late Effects Following Hematopoietic Cell Transplant for Childhood Hematologic Malignancies
265. Bosutinib in Elderly Chronic Myeloid Leukemia (BEST)
266. Treosulfan, Fludarabine Phosphate, and Total-Body Irradiation in Treating Patients With Hematological Cancer Who Are Undergoing Umbilical Cord Blood Transplant
267. Study of ProTmune for Allogeneic HCT in Adult Patients With Hematologic Malignancies
268. A Study of HS-10382 in Patients With Chronic Myeloid Leukemia.
269. Condition Vasoregulation Function Endothelium in Patients With CML Getting TKI II Generation Bosutinib
270. Precision Dosing of Tyrosine Kinase Inhibitors in CML Patients
271. Imatinib or Nilotinib With Pegylated Interferon-α2b in Chronic Myeloid Leukemia
272. Reduced-Intensity Conditioning Before Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Malignancies
273. Adoptive Immunotherapy in Relapsed Hematological Malignancy: Early GVHD Prophylaxis
274. Determining Change in Cardiovascular and Metabolic Risks in Patients With Chronic Phase Chronic Myeloid Leukemia Receiving BCR-ABL Tyrosine Kinase Inhibitor First-Line Therapy in the United States
275. Sirolimus/Tacrolimus Versus Tacrolimus/Methotrexate for Preventing Graft-Versus-Host Disease (GVHD) (BMT CTN 0402)
276. A Bioequivalence Study of Dasatinib Tablet
277. Decitabine and HQP1351-based Chemotherapy Regimen for the Treatment Advanced CML (Case-Only)
278. Iclusig PMS in CML or Ph+ALL Patients
279. 木犀草素对白血病K562/ADR细胞多药耐药的 逆转作用及机制研究.
280. Cytochrome P450 Inhibition to Decrease Dosage of Dasatinib for Chronic Myelogenous Leukemia
281. Pharmacists Coordinated Care Oncology Model (PCOM) for Patients Taking Oral Anti-cancer Medications
282. Nonmyeloablative Allogeneic Transplant (Mini-allo)
283. Unrelated Donor Stem Cell Transplantation
284. Conditioning Regimen and the Transplantation of Unrelated Donor Umbilical Cord Blood in Patients With Hematologic Malignancies.
285. French Study to Highlight the Unmet Treatment Needs of 3L+ CP-CML and With T315I-mutated CML Patients
286. Study Conducted Among Patients With CML
287. Shorter Course Tacro After NMA, Related Donor PBSCT With High-dose Posttransplant Cy for Hard-to-Engraft Malignancies
288. Observational Study in Adults With Imatinib-resistant/Intolerant Chronic Myeloid Leukemia Treated With Nilotinib (CML0609)
289. Retrospective Evaluation of CML Patients in the National Compassionate Program
290. Allogeneic Hematopoietic Cell Transplantation From HLA-matched Donor After Flu-Mel-PTCy Versus Flu-Mel-ATG Reduced-intensity Conditioning (HLA)
291. Open-Label Study Evaluating Dasatinib Therapy Discontinuation in Patients With Chronic Phase Chronic Myeloid Leukemia With Stable Complete Molecular Response (DASFREE)
292. CD34+ Enriched Transplants From HLA-Compatible Patients With Hematologic Malignancies (2019-KOE-001)
293. 'Peripheral Blood Dipeptidylpeptidase IV (CD26) Positive Leukemic Stem Cells in Chronic Myeloid Leukemia as a Diagnostic Marker'
294. Multicenter Single-arm Pilot Study Evaluating Efficacy of Nilotinib in CML Patients With Molecular Relapse After Glivec Discontinuation Within the Context of the STIM Trials (STIM and STIM2) (NiloPost-STIM)
295. Evaluation of a Cardiovascular Active Prevention in Chronic Myeloid Leukemia on the Cardiovascular Morbi-mortality (PALERMO)
296. IIT PH1 KDS-1001 in Patients With CML
297. The Efficacy and Safety of Switching to Flumatinib Versus Dasatinib After Imatinib-related Low-grade Adverse Events in CML-CP Patients
298. Dose Reduced Dasatinib (70 mg Daily) as First-line Treatment for Newly Diagnosed CML-CP
299. Treatment With Olverembatinib in CML-CP Patients Who Failed to at Least Two Previously Administered Second-generation TKIs.
300. Retro-prospective Observational Study on Risk of Progression in CP-CML Patients Eligible for TKI Discontinuation
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.